Infectious disease
Although the COVID-19 pandemic is waning in the U.S., it’s not completely over and there are some concerns, particularly with the delta variant, which originated in India. Here’s a look.
It was a busy week for clinical trial news. Here’s a look.
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
New data continues to emerge that seems to add to the possibility of COVID-19 originating from a lab leak at China’s Wuhan Institute of Virology.
A new class of compounds currently in development against acute myeloid leukemia has been discovered to block coronavirus reproduction in human lung cells.
The analysis showed that the Pfizer and Oxford/AstraZeneca vaccines can protect patients from being hospitalized by as much as 90 percent.
Last summer, claims that the deadly SARS-CoV-2 virus emerged from a virology lab in Wuhan were generally dismissed by the scientific community as right-wing conspiracy theories. A year later, the theory isn’t sounding so far-fetched.
With COVID-19 ducking for cover and going into an almost full retreat across the U.S., Americans are throwing caution – and masks – to the wind. But many are still nervous, and wondering: How do we protect ourselves in this brave new normal?
Concerns over vaccination links to heart inflammation are valid, a U.S. Centers for Disease Control and Prevention advisory committee announced this afternoon.
Crisis has a way of opening doors of opportunity for fraud around the globe. The COVID-19 pandemic has brought not only a fresh slew of financial schemes, but pharmaceutical fraud as well.
PRESS RELEASES